a Faculty of Pharmacy , DIT University , Dehradun , India.
b School of Pharmaceutical Education and Research , Jamia Hamdard , New Delhi , India.
Artif Cells Nanomed Biotechnol. 2018;46(sup2):1188-1198. doi: 10.1080/21691401.2018.1481863. Epub 2018 Jul 10.
The epidermal growth factor receptor (EGFR) is a cell surface receptor belonging to erythroblastic leukemia viral oncogene homologue (ErbB) family of tyrosine kinase. It plays critical role in the regulation of cell proliferation, survival and differentiation. The EGFR receptor is crucial in a variety of tumor development due to unlikely triggered by receptor overexpression, chromosomal mutation and or ligand-dependent receptor dimerization. The EGFR inhibition established a major therapeutic target in cancer therapy. The signal transduction pathway of EGFR is directly involved in tumor pathogenesis and progression. The combinatorial approach with EGFR inhibitors bring novel therapeutic regime with proved clinical efficacy. This critique briefly addressed EGFR receptor characteristics, worldwide report on various cancers and EGFR based potential targeting modalities in skin, breast, ovary, brain, lungs, pancreas, gastric and colorectal tumors and molecular pathways involved in EGFR targeting.
表皮生长因子受体（EGFR）是一种细胞表面受体，属于酪氨酸激酶的红细胞白血病病毒致癌基因同源物（ErbB）家族。它在细胞增殖、存活和分化的调节中起着关键作用。由于受体过表达、染色体突变和/或配体依赖性受体二聚化的触发，EGFR 受体在多种肿瘤的发生发展中至关重要。EGFR 抑制已成为癌症治疗的主要治疗靶点。EGFR 的信号转导途径直接参与肿瘤的发病机制和进展。EGFR 抑制剂的联合应用带来了新的治疗方案，并已证明具有临床疗效。这篇综述简要介绍了 EGFR 受体的特征、全球范围内各种癌症的报告以及 EGFR 在皮肤、乳腺、卵巢、脑、肺、胰腺、胃和结直肠肿瘤中的潜在靶向模式，以及参与 EGFR 靶向的分子途径。
